secwatch / observer
8-K filed May 15, 2025, 7:59 PM ET CIK 0001564824
M&A confidence high sentiment neutral materiality 0.85

Allakos Inc.: M&A transaction — Allakos acquired by Concentra Biosciences for $0.33/share; delisting from Nasdaq

Allakos Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Alexander

Director
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
each of Robert Alexander, Ph.D., Robert E. Andreatta, Neil Graham, M.D., Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
Departed

Dolca Thomas

Director
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
Appointed

Thomas Wei

Chief Business Officer
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Thomas Wei, Chief Business Officer
Departed

Paul Walker

Director
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Paul Walker resigned from the board of directors
Departed

Robert Alexander

Officer
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Dr. Alexander, Baird Radford and Adam Tomasi have resigned from their respective positions as officers of the Company
Departed

Baird Radford

Officer
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Baird Radford and Adam Tomasi have resigned from their respective positions as officers of the Company
Departed

Amy L. Ladd

Director
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
Appointed

Ryan Cole

Chief Operating Officer
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Ryan Cole, Chief Operating Officer
Appointed

Michael Hearne

Chief Financial Officer
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Michael Hearne, Chief Financial Officer
Departed

Steven P. James

Director
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
Departed

Adam Tomasi

Officer
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Adam Tomasi have resigned from their respective positions as officers of the Company
Departed

Robert E. Andreatta

Director
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Robert E. Andreatta, Neil Graham, M.D., Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
Appointed

Kevin Tang

Director
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang
Appointed

Kevin Tang

Chief Executive Officer
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Mr. Tang, Chief Executive Officer
Appointed

Stew Kroll

Chief Development Officer
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Stew Kroll, Chief Development Officer
Departed

Neil Graham

Director
Allakos Inc.
Effective
2025-05-15
Filed
May 15, 2025, 7:59 PM ET
Neil Graham, M.D., Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Alexander resigned as Director at Allakos Inc..

Action
resigned
Role
Director
Exact text from the filing
each of Robert Alexander, Ph.D., Robert E. Andreatta, Neil Graham, M.D., Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dolca Thomas resigned as Director at Allakos Inc..

Action
resigned
Role
Director
Exact text from the filing
Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Wei was appointed as Chief Business Officer at Allakos Inc..

Action
became
Role
Chief Business Officer
Exact text from the filing
Thomas Wei, Chief Business Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Walker resigned as Director at Allakos Inc..

Action
resigned
Role
Director
Exact text from the filing
Paul Walker resigned from the board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Alexander resigned as Officer at Allakos Inc..

Action
resigned
Role
Officer
Exact text from the filing
Dr. Alexander, Baird Radford and Adam Tomasi have resigned from their respective positions as officers of the Company
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Baird Radford resigned as Officer at Allakos Inc..

Action
resigned
Role
Officer
Exact text from the filing
Baird Radford and Adam Tomasi have resigned from their respective positions as officers of the Company
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Amy L. Ladd resigned as Director at Allakos Inc..

Action
resigned
Role
Director
Exact text from the filing
Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Ryan Cole was appointed as Chief Operating Officer at Allakos Inc..

Action
became
Role
Chief Operating Officer
Exact text from the filing
Ryan Cole, Chief Operating Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Hearne was appointed as Chief Financial Officer at Allakos Inc..

Action
became
Role
Chief Financial Officer
Exact text from the filing
Michael Hearne, Chief Financial Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Steven P. James resigned as Director at Allakos Inc..

Action
resigned
Role
Director
Exact text from the filing
Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Tomasi resigned as Officer at Allakos Inc..

Action
resigned
Role
Officer
Exact text from the filing
Adam Tomasi have resigned from their respective positions as officers of the Company
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Andreatta resigned as Director at Allakos Inc..

Action
resigned
Role
Director
Exact text from the filing
Robert E. Andreatta, Neil Graham, M.D., Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Tang was appointed as Director at Allakos Inc..

Action
became
Role
Director
Exact text from the filing
The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Tang was appointed as Chief Executive Officer at Allakos Inc..

Action
became
Role
Chief Executive Officer
Exact text from the filing
Mr. Tang, Chief Executive Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Stew Kroll was appointed as Chief Development Officer at Allakos Inc..

Action
became
Role
Chief Development Officer
Exact text from the filing
Stew Kroll, Chief Development Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Graham resigned as Director at Allakos Inc..

Action
resigned
Role
Director
Exact text from the filing
Neil Graham, M.D., Steven P. James, Amy L. Ladd, M.D., Dolca Thomas, M.D. and Paul Walker resigned from the board of directors
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Allakos Inc. underwent a change of control involving Concentra Biosciences, LLC for $0.33 per Share in cash (closed 2025-05-15).

Action
change of control
Counterparty
Concentra Biosciences, LLC
Consideration
$0.33 per Share in cash
Closing
2025-05-15
Exact text from the filing
15, 2025, Merger Sub completed a tender offer to purchase all of the C ompany’s outstanding shares of common stock, par value $0.001 per share (the “ Shares ”), in exchange for $0.33 in cash per Share (the “ Offer Price ”), subject to and in accordance with the terms and conditions set forth in the Offer to Purchase, dated April 15, 2025 (the “ Offer to
View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Source: SEC EDGAR
accession 0001140361-25-019156
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.